Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06343779 · ClinicalTrials.gov registry record · Phase 3
Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
A Phase 3 study, sponsored by Pharvaris Netherlands B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 134
- Enrollment target
NCT06343779 is a Phase 3 study that has completed, run by Pharvaris Netherlands B.V.. The registered enrollment target is 134 participants.
The verdict
NCT06343779, a Phase 3 study, has completed, sponsored by Pharvaris Netherlands B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 134 participants
- Enrollment target
Study Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in participants ≥12 to ≤75 years of age with HAE type 1, type 2, or type 3, a proportion of whom are using long-term prophylactic medication for HAE.
Interventions
- DRUG Deucrictibant, Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2025-10-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06343779
The ClinicalTrials.gov registry entry for NCT06343779 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pharvaris Netherlands B.V., which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Deucrictibant, Placebo is the first listed.
NCT06343779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06343779 about?
NCT06343779 is a clinical study titled "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-treatment cross-over study to evaluate the efficacy and safety of orally administered deucrictibant compared to placebo for the on-demand treatment of HAE attacks, including non-severe laryngeal attacks, in par...
What is the current status of trial NCT06343779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 134 participants. The study started on 2024-02-26. Estimated completion is 2025-10-17.
What interventions are being tested in trial NCT06343779?
The interventions under investigation include: Deucrictibant, Placebo (DRUG).
Who is sponsoring clinical trial NCT06343779?
This trial is sponsored by Pharvaris Netherlands B.V., which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.